Actively Recruiting
Patients With Congenital Myasthenic Syndrome Will be Treated With Mesenchymal Stem Cell Exosome Solution
Led by The Foundation for Orthopaedics and Regenerative Medicine · Updated on 2025-11-10
20
Participants Needed
3
Research Sites
208 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Patients with Congenital Myasthenic Syndrome will be treated with Mesenchymal Stem Cell Exosome solution.
CONDITIONS
Official Title
Patients With Congenital Myasthenic Syndrome Will be Treated With Mesenchymal Stem Cell Exosome Solution
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients must have a diagnosis of Congenital Myasthenic Syndrome confirmed by a licensed physician
- Patients must be able to provide informed consent or have a guardian who can
- Patients must be able to travel to the treatment site
You will not qualify if you...
- Pregnant patients are excluded
- Patients with active cancer (malignancy) at screening are excluded
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
Prodromos Stem Cell Institute
Naples, Florida, United States, 34102
Actively Recruiting
2
Prodromos Stem Cell Institute
Irving, Texas, United States, 75039
Actively Recruiting
3
Medical Surgical Associates Center
St John's, Antigua and Barbuda
Actively Recruiting
Research Team
C
Chadwick Prodromos
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here